Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

464 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Novel Sample Selection Approach to Aid the Identification of Factors That Correlate With the Control of HIV-1 Infection.
Makinde J, Nduati EW, Freni-Sterrantino A, Streatfield C, Kibirige C, Dalel J, Black SL, Hayes P, Macharia G, Hare J, McGowan E, Abel B, King D, Joseph S; IAVI Protocol C Investigators; Hunter E, Sanders EJ, Price M, Gilmour J. Makinde J, et al. Among authors: gilmour j. Front Immunol. 2021 Mar 11;12:634832. doi: 10.3389/fimmu.2021.634832. eCollection 2021. Front Immunol. 2021. PMID: 33777023 Free PMC article.
Viral inhibition assay: a CD8 T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates.
Spentzou A, Bergin P, Gill D, Cheeseman H, Ashraf A, Kaltsidis H, Cashin-Cox M, Anjarwalla I, Steel A, Higgs C, Pozniak A, Piechocka-Trocha A, Wong J, Anzala O, Karita E, Dally L, Gotch F, Walker B, Gilmour J, Hayes P. Spentzou A, et al. Among authors: gilmour j. J Infect Dis. 2010 Mar;201(5):720-9. doi: 10.1086/650492. J Infect Dis. 2010. PMID: 20132004
Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects.
Howles S, Guimarães-Walker A, Yang H, Hancock G, di Gleria K, Tarragona-Fiol T, Hayes P, Gilmour J, Bridgeman A, Hanke T, McMichael A, Dorrell L. Howles S, et al. Among authors: gilmour j. Vaccine. 2010 Oct 21;28(45):7306-12. doi: 10.1016/j.vaccine.2010.08.077. Epub 2010 Sep 16. Vaccine. 2010. PMID: 20816902 Clinical Trial.
AIDS vaccines and preexposure prophylaxis: is synergy possible?
Excler JL, Rida W, Priddy F, Gilmour J, McDermott AB, Kamali A, Anzala O, Mutua G, Sanders EJ, Koff W, Berkley S, Fast P. Excler JL, et al. Among authors: gilmour j. AIDS Res Hum Retroviruses. 2011 Jun;27(6):669-80. doi: 10.1089/AID.2010.0206. Epub 2010 Dec 16. AIDS Res Hum Retroviruses. 2011. PMID: 21043994 Free PMC article. Review.
Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa.
Price MA, Wallis CL, Lakhi S, Karita E, Kamali A, Anzala O, Sanders EJ, Bekker LG, Twesigye R, Hunter E, Kaleebu P, Kayitenkore K, Allen S, Ruzagira E, Mwangome M, Mutua G, Amornkul PN, Stevens G, Pond SL, Schaefer M, Papathanasopoulos MA, Stevens W, Gilmour J; IAVI Early Infection Cohort Study Group. Price MA, et al. Among authors: gilmour j. AIDS Res Hum Retroviruses. 2011 Jan;27(1):5-12. doi: 10.1089/aid.2010.0030. Epub 2010 Nov 23. AIDS Res Hum Retroviruses. 2011. PMID: 21091377 Free PMC article.
Equivalence of ELISpot assays demonstrated between major HIV network laboratories.
Gill DK, Huang Y, Levine GL, Sambor A, Carter DK, Sato A, Kopycinski J, Hayes P, Hahn B, Birungi J, Tarragona-Fiol T, Wan H, Randles M, Cooper AR, Ssemaganda A, Clark L, Kaleebu P, Self SG, Koup R, Wood B, McElrath MJ, Cox JH, Hural J, Gilmour J. Gill DK, et al. Among authors: gilmour j. PLoS One. 2010 Dec 14;5(12):e14330. doi: 10.1371/journal.pone.0014330. PLoS One. 2010. PMID: 21179404 Free PMC article.
Measuring human T cell responses in blood and gut samples using qualified methods suitable for evaluation of HIV vaccine candidates in clinical trials.
Kaltsidis H, Cheeseman H, Kopycinski J, Ashraf A, Cox MC, Clark L, Anjarwalla I, Dally L, Bergin P, Spentzou A, Higgs C, Gotch F, Gazzard B, Gomez R, Hayes P, Kelleher P, Gill DK, Gilmour J. Kaltsidis H, et al. Among authors: gilmour j. J Immunol Methods. 2011 Jul 29;370(1-2):43-54. doi: 10.1016/j.jim.2011.05.007. Epub 2011 Jun 12. J Immunol Methods. 2011. PMID: 21669205 Clinical Trial.
Human leukocyte antigen variants B*44 and B*57 are consistently favorable during two distinct phases of primary HIV-1 infection in sub-Saharan Africans with several viral subtypes.
Tang J, Cormier E, Gilmour J, Price MA, Prentice HA, Song W, Kamali A, Karita E, Lakhi S, Sanders EJ, Anzala O, Amornkul PN, Allen S, Hunter E, Kaslow RA; IAVI African HIV Research Network. Tang J, et al. Among authors: gilmour j. J Virol. 2011 Sep;85(17):8894-902. doi: 10.1128/JVI.00439-11. Epub 2011 Jun 29. J Virol. 2011. PMID: 21715491 Free PMC article.
Differences in HIV natural history among African and non-African seroconverters in Europe and seroconverters in sub-Saharan Africa.
Pantazis N, Morrison C, Amornkul PN, Lewden C, Salata RA, Minga A, Chipato T, Jaffe H, Lakhi S, Karita E, Porter K, Meyer L, Touloumi G; CASCADE Collaboration in EuroCoord and ANRS 1220 Primo-CI Study Group. Pantazis N, et al. PLoS One. 2012;7(3):e32369. doi: 10.1371/journal.pone.0032369. Epub 2012 Mar 6. PLoS One. 2012. PMID: 22412867 Free PMC article.
464 results